2-(2-甲氧基-2,3-二氢-1,4-苯并二氧杂环己-2-基)-4,5-二氢-1H-咪唑盐酸盐(1:1) | 109544-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2-(2-甲氧基-2,3-二氢-1,4-苯并二氧杂环己-2-基)-4,5-二氢-1H-咪唑盐酸盐(1:1)
• 英文名称: RX 821002 hydrochloride
• 英文别名: 2-(3-methoxy-2H-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole;hydrochloride
• CAS: 109544-45-8
• 化学式: C12H15ClN2O3
• 分子量: 270.71
• InChiKey: IMPOOMVZVWKSAP-UHFFFAOYSA-N

物化性质

• 溶解度：
  H2O：>20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1.22
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  52.1
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38

文献信息

• Dopamine analog amide
  申请人：——

  公开号：US20010056116A1

  公开（公告）日：2001-12-27

  The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

  该发明涉及使用脂肪酸载体和神经活性药物形成前药。该前药在胃和血液流动环境中稳定，并可通过口服递送。该前药容易穿过血脑屏障。一旦进入中枢神经系统，前药被水解成脂肪酸载体和药物以释放药物。在首选实施方式中，载体是4,7,10,13,16,19二十二碳六烯酸，药物是多巴胺。两者都是中枢神经系统的正常成分。药物和载体之间的共价键通常是酰胺键，这种键可以在胃的条件下存活。因此，前药可以被摄入，并且不会在胃中完全水解成载体分子和药物分子。
• Method for treating nervous system disorders and conditions
  申请人：Abou-Gharbia A. Magid

  公开号：US20060020014A1

  公开（公告）日：2006-01-26

  The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain.

  本发明涉及外消旋1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷、(+)-1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷、外消旋1-(4-甲基苯基)-3-氮杂双环[3.1.0]己烷和(+)-1-(4-甲基苯基)-3-氮杂双环[3.1.0]己烷，以及它们用于治疗某些神经系统障碍和病症的方法，包括血管运动症状（VMS）和慢性疼痛等。
• USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS
  申请人：Deecher Darlene Coleman

  公开号：US20080227850A1

  公开（公告）日：2008-09-18

  The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.

  本发明涉及使用调节去甲肾上腺素水平的化合物和化合物组合物预防和治疗血管运动症状，如由热调节功能障碍引起的潮热等。
• METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS
  申请人：Abou-Gharbia Magid A.

  公开号：US20120190721A1

  公开（公告）日：2012-07-26

  The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain.

  本发明涉及外消旋1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷、(+)-1-(3,4-二氯苯基)-3-氮杂双环[3.1.0]己烷、外消旋1-(4-甲基苯基)-3-氮杂双环[3.1.0]己烷和(+)-1-(4-甲基苯基)-3-氮杂双环[3.1.0]己烷，以及它们治疗某些神经系统疾病和病况的方法，包括血管运动症状（VMS）和慢性疼痛等。
• Organic compounds
  申请人：INTRA-CELLULAR THERAPIES, INC.

  公开号：US10188758B2

  公开（公告）日：2019-01-29

  The present invention relates to novel pyridinoxy phenylpropanamines, their pharmaceutical compositions and methods of use. In addition, the present invention relates to therapeutic methods that penetrate the blood-brain barrier and regulate the norepinephrine and serotonin transporters (“NET/SERT”).

  本发明涉及新型吡啶氧基苯丙胺、其药物组合物和使用方法。此外，本发明还涉及可穿透血脑屏障并调节去甲肾上腺素和血清素转运体（"NET/SERT"）的治疗方法。